Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine versus imipramine for diarrhea-predominant irritable bowel syndrome
IRCT20190703044084N1Phase 2Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Duloxetine + dicyclomine with Imipramine + dicyclomine (2 arms). Primary endpoints: Number of emergency defecations per day, Number of days with bloating per week and 2 more. Started Aug 2019; status: completed.
02
Drugs
duloxetineimipraminedicyclomine
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on IRCT20190703044084N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190703044084N1.